Has Christopher Aderman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $211,430 in general payments to Christopher Aderman, MD across 253 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Aderman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Aderman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Aderman, MD

Retina Specialist · Troutdale, ORNPI 1912260381

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $153,941 of the $211,430 with a category attached, or 72.8%. Regeneron Healthcare Solutions, Inc. accounts for 61.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $72,033 and has fallen 52.7% since, to $34,089 in 2025. Among retina specialist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$211,430in general payments, 2019–2025

Across 253 payments — averaging $835.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$131K
Astellas Pharma US Inc$47K
Genentech USA, Inc.$15K
Regeneron$10K
Apellis Pharmaceuticals, Inc.$3K
Novartis$3K
plus $1K from 8 others

$1,470,141in research payments, 2019–2025

Across 589 payments — averaging $2496.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$1.3M
Kyowa Kirin, Inc.$154K
Boehringer Ingelheim International GmbH$64K

What the payments were for

Consulting fees$29,39114%
Speaking & faculty fees$153,94173%
Travel & lodging$19,6119%
Food & beverage$8,4614%
Education$260%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	98	$130,757
Astellas Pharma US Inc	48	$47,195
Genentech USA, Inc.	37	$15,207
Regeneron	18	$10,215
Apellis Pharmaceuticals, Inc.	6	$3,377
Novartis	18	$3,287
Genentech, Inc.	10	$733
Alimera Sciences, Inc.	2	$239
AbbVie	9	$131
Astellas Pharma Global Development	2	$91
Dutch Ophthalmic, USA	1	$80
Harrow Eye, LLC	2	$65
Alcon	1	$32
Ocular Therapeutix, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EYLEA HD$70,935
EYLEA$68,470
Izervay$46,428
VABYSMO$8,315
Lucentis$6,882
BEOVU$2,329
Syfovre$1,443
YUTIQ$154
Iluvien$154
SUSVIMO$150

How this compares

$211,430 in reported general payments places this provider in the 95th percentile of 36 retina specialist providers in Oregon.

See all retina specialist providers in Oregon →

Medicare billing

Part B allowed, 2024

$3,631,172

Medicare patients

696

Services billed

31,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	133	$6,034
Brimonidine Tartrate	39	$1,468
ValacyclovirValacyclovir Hcl	11	$1,309
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	68	$991
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim	43	$383
Latanoprost	33	$227
Timolol Maleate	19	$188

Paid to pharmacies, not to this prescriber.

Other retina specialist in Troutdale

Brian Chan KaiPortland$155K
Peter KarthNorth Bend$119K
John HyattAshland$57K
Brandon LujanPortland$33K
Andreas LauerPortland$17K
Albert EdwardsEugene$9K
Sirichai PasadhikaPortland$6K
Ryan ConstantineRedmond$5K
David WilsonPortland$5K
Timothy GardHillsboro$3K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →